HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation.

Abstract
Gray platelet syndrome (GPS) is an inherited disorder. Patients harboring GPS have thrombocytopenia with large platelets lacking α-granules. A long-term complication is myelofibrosis with pancytopenia. Hematopoietic stem cell transplant (HSCT) could be a curative treatment. We report a male GPS patient with severe pancytopenia, splenomegaly and a secondary myelofibrosis needing red blood cells transfusion. He received an HSCT from a 10/10 matched HLA-unrelated donor after a myeloablative conditioning regimen. Transfusion independence occurred at day+21, with a documented neutrophil engraftment. At day+ 180, we added ruxolitinib to cyclosporine and steroids for a moderate chronic graft versus host disease (GVHD) and persistent splenomegaly. At day+240 GVHD was controlled and splenomegaly reduced. Complete donor chimesrism was documented in blood and marrow and platelets functions and morphology normalized. At day+ 720, the spleen size normalized and there was no evidence of marrow fibrosis on the biopsy. In GPS, HSCT may be a curative treatment in selected patients with pancytopenia and myelofibrosis.
AuthorsRémi Favier, Xavier Roussel, Sylvain Audia, Jean Claude Bordet, Emmanuel De Maistre, Pierre Hirsch, Anne Neuhart, Isabelle Bedgedjian, Vasiliki Gkalea, Marie Favier, Etienne Daguindau, Paquita Nurden, Eric Deconinck
JournalPlatelets (Platelets) Vol. 31 Issue 4 Pg. 536-540 (May 18 2020) ISSN: 1369-1635 [Electronic] England
PMID31502501 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Cyclosporine
Topics
  • Adult
  • Blood Platelets (metabolism, pathology, ultrastructure)
  • Cyclosporine (therapeutic use)
  • Graft vs Host Disease (drug therapy)
  • Gray Platelet Syndrome (drug therapy, physiopathology, therapy)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Microscopy, Electron, Transmission
  • Nitriles
  • Primary Myelofibrosis (therapy)
  • Pyrazoles (therapeutic use)
  • Pyrimidines
  • Splenomegaly (drug therapy, etiology)
  • Time Factors
  • Transplantation Conditioning

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: